Ben-Gurion University of the Negev

Magneto Thrombectomy Solutions Announces Successful First-in-Human Results for Treatment of Pulmonary Embolism (PE)

Retrieved on: 
Tuesday, May 10, 2022
Transfer, Artery, Solution, Thrombectomy, Company, Stroke, Safety, Data, Leg, Patient, Pulmonary embolism, Thrombus, BGU, Aarhus University Hospital, FIH, Ben-Gurion University of the Negev, Breathe Me, BIOMED, PE, Prognosis, Efficiency, PERT, Embolism, Technology, CEO, Association of British HealthTech Industries, Medical imaging, Pharmaceutical industry, Computer data storage, Birth control, Magneto, Incentive

OR YEHUDA, Israel, May 10, 2022 /PRNewswire/ -- Magneto Thrombectomy Solutions (Magneto), a medical devices company developing innovative thrombectomy solutions for the treatment of ischemic stroke and pulmonary embolism, presented today successful first-in-human (FIH) results showing safety and feasibility of the eTrieve™ system, a novel catheter based on electric fields for removing blood clots, in patients with acute pulmonary embolism (PE). The data, presented today at Biomed Israel 2022, the premier international Life Science and HealthTech conference in Israel (May 10-12, Tel Aviv), showed a significant reduction in RV/LV ratio and alleviation of PE associated symptoms.

Key Points: 
  • "We are very pleased with our FIH results, which confirm the safety and efficiency of our innovative technology, as previously demonstrated in preclinical studies," said Benny Dilmoney, CEO of Magneto.
  • "Our novel catheter is a groundbreaking solution that can transform treatment of conditions caused by blood clots, such as pulmonary embolism.
  • PE is a rapidly growing market enhanced by the Pulmonary Embolism Response Team (PERT) approach for PE management.
  • Magneto Thrombectomy Solutions is developing innovative thrombectomy solutions for the treatment of ischemic strokes and pulmonary embolisms.

Madrigal Mental Care Develops Treatment for Post-Traumatic Stress Disorder Based on Psychedelic Drugs

Retrieved on: 
Monday, May 9, 2022
Transfer, People, Ben-Gurion University of the Negev, LSD, Psilocybin, Selective serotonin reuptake inhibitor, Tic disorder, Lysergic acid diethylamide, Department, Brain, Senior, Biochemistry, Student, Post-traumatic stress disorder, Lists of diseases, Company, Ketamine, Incubator, Nanoparticle, Depression, PayPal, Time, Cognition, Norepinephrine, Nanotechnology, Entrepreneurship, BGU, BGN, Diagnosis, Serotonin, Business development, Deutsche Telekom, Anxiety, Pharmacology, Patent, Serotonin–norepinephrine reuptake inhibitor, Wallace H. Coulter Department of Biomedical Engineering, MDMA, Trauma, Dell EMC, Mescaline, Psychotherapy, Government Hospital For Mental Care, PTSD, Technology, Research, Lockheed, Growth, Association of British HealthTech Industries, InterContinental, Online gambling, Pharmaceutical industry, BIOMED

BEER-SHEVA, Israel, May 9, 2022 /PRNewswire/ -- Madrigal Mental Care, a biopharmaceutical company developing a breakthrough delivery system for psychedelic drugs, introduces its novel nanotechnology for the treatment and prevention of post-traumatic stress disorder (PTSD) at Biomed Israel 2022, the premier international Life Science and HealthTech conference in Israel, on May 10-12, 2022, at the David InterContinental Hotel in Tel Aviv, Israel.

Key Points: 
  • "An increasing number of studies point to the advantages of using psychedelic drugs for the treatment of psychiatric disorders such as PTSD, depression, anxiety, obsessive compulsive disorder, and even addiction, with low doses," said Prof. Sintov.
  • The nanoparticles are biodegradable and provide a significant advantage over common practices in terms of stability and accuracy," stated David Gabay, Co-Founder, and Chairman of Madrigal Mental Care.
  • Based on Databridge, the psychedelic market is expected to reach 40$ billion by 2027 in the medical arena alone.
  • Madrigal Mental Care aims to redefine the future of mental health care by using cutting-edge, breakthrough nanotechnology to deliver psychedelic drugs.

Cipia Announces Yehuda Holtzman as New CEO

Retrieved on: 
Sunday, May 8, 2022
Board, Ben-Gurion University of the Negev, Tel Aviv Stock Exchange, TASE, University, American, Electronics, Engineering, OTI, TEL, Wireless, CPIA, Industry, Leadership, Retirement, Board of directors, Sale, Corning Inc., DMS, Solution, CEO, Technology, Research, AI, University of Brighton, NFC, IPO, Acquisition, Management

TEL AVIV, Israel, May 8, 2022 /PRNewswire/ -- Cipia (TASE: CPIA), a computer vision AI in-cabin automotive solutions provider, today announced Yehuda Holtzman as its new CEO. The Board of Directors selected a seasoned entrepreneur and CEO with rich experience in both private and public tech companies, to replace retiring, outgoing CEO David Tolub, who led Cipia through its shift to the automotive market as well as the company's recent IPO.

Key Points: 
  • TEL AVIV, Israel, May 8, 2022 /PRNewswire/ -- Cipia (TASE: CPIA), a computer vision AI in-cabin automotive solutions provider, today announced Yehuda Holtzman as its new CEO.
  • Holtzman brings over 25 years of business, technological and managerial experience as a CEO of technology and communications companies to lead Cipia.
  • "I am excited to join Cipia as the company enters such a crucial time in the driver monitoring industry," said Yehuda Holtzman, CEO of Cipia.
  • "It has been a privilege to lead Cipia over the past number of years," said David Tolub, outgoing CEO of Cipia.

Medical Technology Specialist Joins CD&R's Healthcare Team

Retrieved on: 
Tuesday, May 3, 2022
Ben-Gurion University of the Negev, Investment, CD, Culture, NEW, Johnson & Johnson, Harvard Business School, Clayton, Dubilier & Rice, Company, Electrophysiology, Global Network for Advanced Management, CD&R, Leadership, DePuy, Elective surgery, R, Spine, Cardiology, Dubilier, Multimedia, Pharmaceutical industry, Medicine

NEW YORK, May 3, 2022 /PRNewswire/ -- Clayton, Dubilier & Rice announced Nadav Tomer, a medical technology specialist, has been named an Operating Advisor to CD&R funds. Mr. Tomer will work with CD&R's healthcare team to help source new investments and advise the funds' healthcare businesses.

Key Points: 
  • Mr. Tomer will work with CD&R's healthcare team to help source new investments and advise the funds' healthcare businesses.
  • "Nadav brings a strong track record of execution and deep experience leading global businesses in the medical technology field across a range of therapeutic areas and disciplines," said CD&R Partner Derek Strum.
  • "We believe he will be highly valuable in creating differentiated angles and enhancing our ability to underwrite high conviction, execution-based investment cases as we look to expand our investments in medical technology."
  • "I look forward to working with the talented CD&R team of investment and operating professionals and contributing to the continued success of the CD&R funds and their portfolio companies in the medical technology sector."

Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022

Retrieved on: 
Monday, April 25, 2022
EMA, Nitric oxide, NTM, Respiratory syncytial virus, Marketing, Pulmonology, Artery, Population, COVID-19, Adult, RSV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ben-Gurion University of the Negev, Annual report, Urinary tract infection, Nontuberculous mycobacteria, Bacteria, Mycobacterium, Food, Outline of health sciences, Patient, Fungus, CAVP, Parasitism, Atmosphere of Earth, Technology, Company, SEC, Forward-looking statement, Faculty, McMaster Faculty of Health Sciences, Bronchiolitis, Mark (given name), Pulmonary hypertension, Safety, Hypoxemia, Beersheba, Policy, Respiratory distress syndrome, FDA, PAS, Virus, NO, Time, NO2, Pharmaceutical industry, Vaccine

The Beyond Air team continues to execute in this challenging pandemic environment and move the Beyond Air pipeline forward.

Key Points: 
  • The Beyond Air team continues to execute in this challenging pandemic environment and move the Beyond Air pipeline forward.
  • Professor, Head of Department Pediatrics, Soroka University Medical Center; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Dr. Goldbart presented the results of the long-term study at the PAS 2022 Meeting in an oral presentation titled, 1179165 Long-term effects of inhaled nitric oxide in infants with bronchiolitis a multi center study.
  • The presentation is available on the Events page of the Beyond Air website ( click here ).

Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

Retrieved on: 
Wednesday, March 30, 2022
Company, Private Securities Litigation Reform Act, Agitation, NASDAQ, Autism, Ben-Gurion University of the Negev, Chemical engineering, Central nervous system, IND, THC, Research, SEC, Risk, Coronavirus Scientific Advisory Board (Turkey), Status epilepticus, Medicine, Targeted drug delivery, Pain, Peripheral nervous system, Negev, Nanotechnology, Safety, Chronic pain, Intention, U.S. Securities and Exchange Commission, CBD, TEL, CB2, GLOBE, Physician, SAB, Tourette syndrome, Annual report, Alzheimer's disease, Technology, Cannabinoid, MIT, Pharmaceutical industry, Technion – Israel Institute of Technology

TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroeder will advise the Company on the formulation development of SCI-160 to enhance the proprietary synthetic CB2 receptor agonist’s biological effect and extend effect duration.

Key Points: 
  • As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain.
  • Prof. Schroeder will advise the Company on the formulation development of SCI-160 to enhance the proprietary synthetic CB2 receptor agonists biological effect and extend effect duration.
  • The Company previously achieved positive results in a series of pre-clinical trials in which the efficacy and safety of SCI-160 was demonstrated in both acute and chronic pain.
  • Prof. Schroeder received three degrees in Chemical Engineering from the Ben-Gurion University of the Negev and his postdoctoral training took place at MIT.

Former GM Radar Lead, Gonen Barkan, Joins Arbe as Chief Radar Officer

Retrieved on: 
Monday, March 21, 2022
Private Securities Litigation Reform Act, Risk, GM, Analysis, Forward-looking statement, Computer science and engineering, Electrical engineering, SEC, Perception, Financial condition report, Barkan, Mobility as a service, Signal processing, U.S. Securities and Exchange Commission, Solution, Conversation, Supercruise, Robotics, Computer science, Security (finance), PLC, Industry, Technology, Safety, Securities Exchange Act of 1934, HW, Securities Act of 1933, Ben-Gurion University of the Negev, ASIC, IOT, Nasdaq, TEL, Result, General Motors, Communication, Hummel Ultracruiser, SW, Architecture, Bachelor of Science, Instrumentation, Radar, SF

TEL AVIV, Israel, March 21, 2022 /PRNewswire/ -- Arbe Robotics Ltd. (Nasdaq: ARBE) ("Arbe"), a global leader in next-generation 4D Imaging Radar Solutions, announced today that former General Motors Radar Development Lead, Gonen Barkan, joins Arbe as Chief Radar Officer.

Key Points: 
  • TEL AVIV, Israel, March 21, 2022 /PRNewswire/ -- Arbe Robotics Ltd. (Nasdaq: ARBE) ("Arbe"), a global leader in next-generation 4D Imaging Radar Solutions, announced today that former General Motors Radar Development Lead, Gonen Barkan, joins Arbe as Chief Radar Officer.
  • "We are excited that industry leader, Gonen Barkan, is joining our team, bringing with him a wealth of expertise and invaluable experience," Arbe Chief Executive Officer Kobi Marenko says.
  • "His contributions to radar innovation at Arbe will undoubtedly make an enormous impact on the automotive industry.
  • By joining Arbe as Chief Radar Officer, Barkan demonstrates his confidence in Arbe's technology, which is revolutionizing radar as a sensor, and its impact on the path of the entire industry."

Playtika Announces Hiring of Vice-President of Blockchain Technology

Retrieved on: 
Thursday, March 10, 2022
NASDAQ, Heart, Business, Intel, Blockchain, Tel Aviv University, MBA, Technology, Doctor of Philosophy, Ben-Gurion University of the Negev, Commerce, Cryptocurrency, Video game, Economics, Playtika

HERZLIYA, Israel, March 10, 2022 /PRNewswire/ -- Playtika Holding Corp. (NASDAQ: PLTK) announced today the hiring of Dr. Jacob Mendel as the company's Vice-President of Blockchain Technology.

Key Points: 
  • HERZLIYA, Israel, March 10, 2022 /PRNewswire/ -- Playtika Holding Corp. (NASDAQ: PLTK) announced today the hiring of Dr. Jacob Mendel as the company's Vice-President of Blockchain Technology.
  • Dr. Mendel will leverage his deep expertise in blockchain technology as the company further explores growth opportunities in GameFi and Web3.0 more broadly.
  • I am thrilled to have Dr. Mendel, one of the world's leading experts in blockchain technology and cybersecurity, join our team to lead this new growth initiative."
  • Prior to joining Playtika, Dr. Mendel led blockchain technology initiatives at Intel and most recently J.P. Morgan.

Medigus: Prof. Nancy Agmon-Levin Joins Polyrizon’s Scientific Advisory Board

Retrieved on: 
Thursday, March 3, 2022
DKFZ, Granuloma, Ben-Gurion University of the Negev, Internal medicine, University of Parma, Lupus, Private Securities Litigation Reform Act, Hives, Immunotherapy, Industry, Hadassah Medical Center, Robotics, Security (finance), German Cancer Research Center, U.S. Securities and Exchange Commission, Ownership, James v Redcats (Brands) Ltd, Chemical substance, Solution, University, MDGS, Digital, Allergy, Administration, Pharmacy, Angioedema, Antiphospholipid syndrome, Immunology, Sheba Medical Center, Degenerative disease, Lists of diseases, Regenerative medicine, Hebrew University of Jerusalem, Faculty, Chemical engineering, Autoimmune disease, GLOBE, Immunodeficiency, Vaccine, Online gambling, Pharmaceutical industry

Tel Aviv, Israel, March 03, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle (“EV”) and charging solutions, announced today that Polyrizon Ltd., a privately held company in which Medigus owns 37.03%, has added Prof. Nancy Agmon-Levin, expert in immunology, allergy, internal medicine, to its scientific advisory board. 

Key Points: 
  • Prof. Agmon- Levin is the Head of the Clinical Immunology, Angioedema and Allergy Unit, Lupus and Autoimmune Diseases Clinic at Sheba Medical Center.
  • Prof. Agmon-Levin is a co-author of numerous scientific articles.
  • Prof. Agmon-Levin joins a scientific advisory board that already includes distinguished professors in the fields of biomaterials, drug delivery systems and nasal administrated products.
  • The current composition of Polyrizons scientific advisory board members include:
    Prof. Smadar Cohen - Distinguished Professor and Director of the Regenerative Medicine and Stem Cell Research Center at Ben Gurion University of the Negev.

PsyRx Announces Appointment of Prof. Itamar Grotto as New Executive Chairman of the Board

Retrieved on: 
Tuesday, February 22, 2022
Depression, GMP, Executive, American Association of Public Health Physicians, Government, COVID-19, Environmental health, TEL, WHO, RTÉ Executive Board, Public health, National health insurance, Ministry, Ben-Gurion University of the Negev, Industry, World, Person, Associate, World Health Organization, Board of directors, Drug combination, Disability, Dalla Lana School of Public Health, School, Infection, TRD, Drug discovery, Epidemiology, CEO, Research, Health promotion, Time, Pharmaceutical industry, Psilocybin, Ibogaine, Health

The appointment follows the recent renewal of the company's license to conduct R&D in Psilocybin and Ibogaine, issued by the Israeli Ministry of Health.

Key Points: 
  • The appointment follows the recent renewal of the company's license to conduct R&D in Psilocybin and Ibogaine, issued by the Israeli Ministry of Health.
  • Prof. Itamar Grotto is a Public Health Physician and Professor of Epidemiology.
  • Between 2018 and 2021 he was a Member of the Executive Board of the World Health organization (WHO).
  • Itay Hecht, CEO and Co-founder of PsyRx, said: "We are honored to be joined by a medical professional of such caliber like Prof. Grotto.